Dr. Rosenbaum, Chief of Psychiatry at Massachusetts General Hospital (MGH) and Professor of Psychiatry at Harvard Medical School, is recognized as one of the world's foremost authorities on mood and anxiety disorders, with a special emphasis on pharmacotherapy of those conditions. His research contributions include extensive participation in the design and conduct of clinical trials of new therapies, the design and implementation of trials to develop innovative treatments for major depression, treatment resistant depression, and panic disorder, studies of psychopathology including comorbidity and subtypes, and studies of longitudinal course and outcomes of those disorders.
Dr. Rosenbaum has authored more than 300 original articles and reviews and has published 12 books. He currently serves on 12 editorial boards of professional journals or newsletters. A particular research interest has been ongoing studies of children at risk for anxiety disorders and depression, which addresses early temperamental differences, such as the profile known as Behavioral Inhibition to the Unfamiliar, as an identifiable early marker of risk for later psychopathology in children at risk.
At MGH, he directs a department of over 500 clinicians and researchers, ranked by U.S. News and World Report to be the #1 Department of Psychiatry in the United States for the past eight years in a row. Dr. Rosenbaum's clinical and consulting practice specializes in treatment-resistant mood and anxiety disorders, and he consults extensively to colleagues on management of these conditions. He lectures widely on related topics, addressing thousands of practitioners annually in a variety of postgraduate educational venues.
Dr. Rosenbaum is President and Executive Director of the MGH Mood and Anxiety Disorders Institute, established with a primary mission to enhance the recognition, understanding and treatment of those disorders. Together with his colleagues, he developed the MGH outpatient service into a world-leading clinic and clinical research center, with specialty programs including the Depression Clinical and Research Program, the Harvard-MGH Bipolar Program, the Anxiety Disorders Program, the Perinatal and Reproductive Psychiatry Program, and the Psychiatric Genetics Program in Mood and Anxiety Disorders, each of which has extensive portfolios of funded research.
Dr. Rosenbaum received his undergraduate degree from Yale College and his medical degree from Yale School of Medicine. He completed his residency and fellowship in Psychiatry at Massachusetts General Hospital, Harvard Medical School.
Dr. Fava has been Director of the Depression Clinical and Research Program at Massachusetts General Hospital since 1990. Dr. Fava obtained his medical degree and completed residency training in endocrinology at the University of Padua School of Medicine. He then moved to the United States and completed residency training in psychiatry at MGH.
Under Dr. Fava's direction, the Depression Clinical and Research Program has become one of the most highly regarded depression programs in the country, a true model for academic programs that link, in a bi-directional fashion, clinical and research work. The number of ongoing projects has grown from five in 1990 to the more than 40 currently.
The clinician-scientists of the Depression Clinical and Research Program conduct research projects in a variety of areas, including neuroimaging, genetics, neurophysiology, neuroendocrinology, pharmacotherapy, neurotherapeutics, and psychotherapy. Dr. Fava has also been successful in obtaining funding for the program, as principal or co-principal investigator, from both the National Institutes of Health and industry for a total of more than $20,000,000 in the past ten years. Dr. Fava's prominence in the field is reflected by his role as the co-principal investigator of STAR*D, the largest study ever conducted in the area of depression.
Dr. Fava has authored or co-authored more than 300 original articles published in medical journals with international circulation. He has also edited four books, and published more than 50 chapters and 400 abstracts. He has received several awards during his career and is on the editorial board of four international medical journals. His major research interests have been the development of effective short-term and long-term strategies in the treatment of depression and depressive subtypes, and the study of treatment-resistant depression. Since 1990, Dr. Fava has also mentored more than 20 trainees who have gone on to become lead investigators in the area of depression.
Dr. Fava is also a well-known national and international speaker, having given more than 200 presentations at national and international meetings during his career in psychiatry. He is currently Vice Chair for the Department of Psychiatry and Director of the Depression Clinical and Research Program at the Massachusetts General Hospital and Professor of Psychiatry at Harvard Medical School.
Dr. Birnbaum is the Director of the Division of Postgraduate Education in the Psychiatry Department at Massachusetts General Hospital, an Assistant Professor of Psychiatry at Harvard Medical School, and has been in clinical practice since 1989 providing clinical consultation services. Dr. Birnbaum received his medical and research doctoral degrees from Boston University School of Medicine and Boston University's Division of Graduate Medical and Dental Sciences. His PhD research was in protein biochemistry elucidating the role of calcium regulation in stimulus response coupling in neural and smooth muscle tissue. His post-doctoral research in molecular neurobiology was completed at Harvard Medical School's Departments of Neurology and Psychiatry under the supervision of Dr. Steven E. Hyman.
Dr. Birnbaum was awarded Ethel Dupont-Warren Foundation, Dana Neuroscience Foundation, and Scottish Rite Schizophrenia Research Grants to pursue his post-doctoral research investigating the induction of immediate early genes in mouse striatum and nucleus accumbens by psychotropic agents. His psychiatry residency training was completed at Massachusetts General Hospital, as was his chief residency in psychopharmacology. He has also received additional post-doctoral training and supervision in psychodynamic, psychoanalytic, and cognitive behavioral modalities of psychotherapy.
He was the Director of Clinical Research and Psychopharmacology at Beth Israel Deaconess Medical Center for 10 years and Senior Psychiatric Administrator to the CareGroup/Lahey Behavioral Health Care System. He was also the Coordinator in Charge of the Psychiatric Applications of Transcranial Magnetic Stimulation (TMS), Laboratory for Magnetic Brain Stimulation, at Beth Israel Deaconess Medical Center.
Dr. Birnbaum has been involved in numerous psychopharmacologic clinical trials investigating the treatment of mood, anxiety, and psychotic disorders. He has lectured widely to multidisciplinary audiences nationally and internationally. He has utilized his dual training in the basic neurosciences and clinical psychiatry to focus his current investigative efforts on the disaggregation of complex behavioral phenotypes.
John A. Fromson is associate director of postgraduate medical education in the department of psychiatry at the Massachusetts General Hospital. Doctor Fromson is an Assistant Clinical Professor of Psychiatry at Harvard Medical School and received the Harvard Medical School Excellence in Tutoring Award for the academic year 2007. He is also the physician editor of the New England Journal of Medicine's online CareerCenter Resource Center.
Doctor Fromson's primary clinical and research activities have centered on issues relating to physician and medical student health, professional development, and patient safety. He was the founding director, served as president, and is currently on the board of Physician Health Services, the primary program in Massachusetts that has become a national model in the prevention, identification, referral to treatment, and monitoring of physicians and medical students with substance use disorders, mental health issues, and physical illness. He is chair of the American Academy of Addiction Psychiatry's Committee on Physician Health, past chair of the American Psychiatric Association's Committee on Physician Health, Illness and Impairment, and past president of the Federation of State Physician Health Programs.
Doctor Fromson is also the immediate past president of the Massachusetts Coalition for the Prevention of Medical Errors. Initiated in 1997 as one of the first coalitions of its kind in the country, it is a statewide collaborative effort to improve patient safety and minimize medical errors. He chaired its Restraint Consensus Group that developed the first statewide best practices for creating restraint-free environments in hospitals, long term care, and psychiatric facilities. He is a member of the board of the Massachusetts Peer Review Organization (Masspro) and also serves on the board of Medically Induced Trauma Support Services (MITSS) that provides services to patients, families, and clinicians affected by medically induced trauma.
He is a trained facilitator of the Stanford Faculty Development Center's End-of-Life Care Program and served on the Executive Committee of the Commonwealth of Massachusetts End-of-Life Commission and on the board of the Massachusetts Compassionate Care Coalition.
For his work in the areas of patient safety and physician and medical student health, Doctor Fromson is the recipient of the Massachusetts Psychiatric Society's 2008 Outstanding Psychiatrist Award for Advancement of the Profession. He is certified by the American Board of Psychiatry and Neurology in psychiatry, child psychiatry, and has added qualifications in addiction psychiatry. He is a Distinguished Fellow of the American Psychiatric Association and Fellow of the American Academy of Child and Adolescent Psychiatry.
Anne E. Becker, MD, PhD, is the Director of the Adult Eating and Weight Disorders Program at Massachusetts General Hospital. She was trained at Harvard Medical School and completed her psychiatric residency at the MGH. She has a doctoral degree in anthropology from the Harvard Graduate School of Arts and Sciences. Dr. Becker is Associate Professor of Medical Anthropology Assistant Professor of Psychiatry at Harvard Medical School.
Dr. Becker's primary research focus is on socio-cultural factors that contribute to risk for eating disorders. She was lead author in recent research that documented a profound impact of television on adolescent girls' body image in Fiji, a small scale indigenous society which had been unexposed to television prior to 1995. She currently has NIMH funding to investigate the impact of social transition on disordered eating in Fijian and mainland Puerto Rican girls. Dr. Becker has authored and co-authored numerous scientific papers and reviews on eating disorders and has written a book, Body, Self, and Society: The View from Fiji, in the cultural context of body image is explored. Dr. Becker is also co-editor in chief of Culture, Medicine and Psychiatry.
Dr. Biederman is Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital, and Professor of Psychiatry at the Harvard Medical School. Dr. Biederman is Board Certified in General and Child Psychiatry.
He has been the recipient of the American Psychiatric Association Blanche Ittelson Award for Excellence in Child Psychiatric Research, the American Academy of Child and Adolescent Psychiatry Charlotte Norbert Rieger Award for Scientific Achievement. He has been inducted into the CHADD “Hall of Fame”. Dr Biederman has also been selected every year since its inception into the “The Best Doctors in America” compilation of the best physicians in the country.
Dr. Biederman has been a mentor to more than 15 junior investigators in the field. He is on the editorial board of multiple journals, a reviewer for most of the Psychiatric journals, and has served as a grant reviewer in the Child Psychopathology and Treatment Review Committee of the NIMH. Dr. Biederman is the author and co-author of more than 500 scientific articles, 500 scientific abstracts, and 70 book chapters.
In 2000, Dr. Biederman pioneered and established a Stanley Foundation Center at the Massachusetts General Hospital dedicated to the treatment of pediatric bipolar disorder. Dr. Biederman was the recipient of the 1998 NAMI Exemplary Psychiatrist award. He was also the recipient of the 2002 NARSAD Senior Investigator award. Since 2002 Dr. Biederman has been Associate Editor and from 2005-2006 Deputy Editor for Child Psychiatry in Biological Psychiatry, ranked as the third most impactful scientific journal in Psychiatry. In 2005 Dr. Biederman was appointed Chair of the section on ADHD at the World Psychiatric Association. He was also recently selected by the Massachusetts Psychiatric Society Awards committee as the recipient of the 2007 Outstanding Psychiatrist Award for Research. In 2007, Dr. Biederman received the Excellence in Research Award from the New England Council of Child and Adolescent Psychiatry. He was also awarded the Mentorship Award from the Department of Psychiatry at the Massachusetts General Hospital in September.
As of March 2007, Dr. Biederman has been ranked as the second highest producer of high-impact papers in psychiatry overall throughout the world with 235 papers cited a total of 7048 times over the past 10 years as determined by the Institute for Scientific Information (ISI). The same organization ranked Dr. Biederman at #1 in terms of total citations to his papers published on ADD/ADHD in the past decade. Dr. Biederman's work is supported by multiple federal and pharmaceutical industry grants.
Dr. Cohen is Director of the Perinatal and Reproductive Psychiatry Clinic Research Program within the Clinical Psychopharmacology Unit of Massachusetts General Hospital (MGH), as well as Associate Professor of Psychiatry at Harvard Medical School. The Perinatal Psychiatry Program, founded in 1987, is a women#39;s health center dedicated to the evaluation and treatment of psychiatric disorders associated with female reproductive function. He completed his residency training and a fellowship at MGH.
Dr. Cohen has been principal investigator on federally funded studies evaluating the risk of depressive relapse during pregnancy and the postpartum period as well as the relationship between mood disorder and reproductive endocrine function among women transitioning to the menopause. He has published numerous original research articles in the area of women's mental health and has edited and contributed to several textbooks in the area of perinatal and reproductive psychiatry.
Dr. Cohen is past recipient of an NIMH Faculty Scholar Award and a Young Investigator Award from the National Association of Research in Schizophrenia and Depression (NARSAD). He has been honored with an Independent Investigator Award from NARSAD to study the course of bipolar illness in pregnancy and the postpartum period, and the Outstanding Psychiatrist Award for Research from the Massachusetts Psychiatric Society. Dr. Cohen currently serves on the Advisory Board to the Office of Research on Women's Health (ORWH) at the National Institute of Health.
Dr. Ellison is Clinical Director, Geriatric Psychiatry Service, at McLean Hospital. He is board certified in adult psychiatry with added qualifications in geriatric psychiatry. Dr. Ellison's clinical work at McLean Hospital focuses on mood disorders and cognitive impairment and he is Director of the hospital's Memory Disorders Clinic. His research interests focus on late life depression and on cognitive impairment in the elderly. He maintains an active private and consulting practice, and teaches psychiatric trainees within the Harvard Medical School System, where is an Associate Professor of Psychiatry.
Dr. Ellison received his medical degree from the University of California, San Francisco, and his master's from the Harvard School of Public Health. His psychiatry residency training was at Massachusetts General Hospital, where he served as chief resident in Emergency Psychiatry (APS) during his final year. Subsequently he had pursued an academic, clinical, and administrative career, serving as chief of a psychiatric emergency service at New England Medical Center, developing a psychopharmacology service at The Cambridge Hospital, and providing medical directorship at a for-profit mental health/substance abuse hospital. He served as chief of an HMO mental health service (at Harvard Vanguard Medical Associates, Burlington Practice), and as chief of psychiatry at a community hospital psychiatry department (Boston Regional Medical Center).
Among the organizations to which he belongs are the American Association for Geriatric Psychiatry, the American Medical Association, Alpha Omega Alpha, the American Psychiatric Association (of which he is a Distinguished Fellow), the American Society of Clinical Psychopharmacology, the Massachusetts Psychiatric Society (of which he was president in 2003-4), and NAMI. He is a reviewer for several journals, has published in the areas of emergency psychiatry, clinical psychopharmacology, and geriatric psychiatry, and has edited six books on mental health topics. His most recent book is Depression in Later Life.
Dr. Fricchione has been at Harvard Medical School (HMS) since 1993 when he was appointed an Associate Professor of Psychiatry and director of the Medical Psychiatry Service at Brigham and Women's Hospital. Since July 2002 he has been Associate Chief of Psychiatry at Massachusetts General Hospital.
Fricchione received his M.D. from New York University School of Medicine. He completed his internship at New York University-Bellevue and Manhattan Veterans Administration Hospitals. He also did his residency in Psychiatry and was Chief Resident at New York University's Bellevue Hospital. He also was a Fellow in Psychosomatic Medicine at Harvard Medical School and Massachusetts General Hospital's Department of Psychiatry from 1982 to 1983. He is board certified in psychiatry and has added qualifications in geriatric psychiatry.
His hospital appointments have included: Massachusetts General Hospital as a psychiatrist in the Psychopharmacology Unit and as a project psychiatrist and physician in the Cardiac Rehabilitation Unit (1982-1983) and the State University of New York at Stony Brook Health Science Center as Director of the Psychiatry Consultation Division. In 1987-88 he was in New Zealand as a Visiting Senior Lecturer and psychiatric consultant at Auckland Hospital. From 1993 to 2000, he worked at Brigham and Women's Hospital as Director of the Medical Psychiatry Service. From 1998 to 2000 he also served as Director of Research at the Mind/Body Medical Institute. He joined the Carter Center in Atlanta, Georgia, while on leave of absence from HMS. While there he worked with Mrs. Rosalynn Carter and former President Jimmy Carter on public and international mental health issues and policy. While at the Carter Center, he directed the Rosalynn Carter Fellowships in Mental Health Journalism. In July 2002 he returned to HMS and to Massachusetts General Hospital as Associate Chief of Psychiatry and Director of the Division of Psychiatry and Medicine and of the Division of International Psychiatry.
Besides his clinical experience in general hospital psychiatry, Dr. Fricchione is committed to education. He has taught in the medical schools at New York University, the State University of New York at Stony Brook, University of Auckland and at Emory University as well as at Harvard Medical School.
Dr. Fricchione has been an active researcher and has published over seventy journal articles since 1983. He has made original contributions to the treatment of patients with catatonia and to the management of cardiac patients who suffer from co-morbid psychiatric conditions. He is a co-author of the MGH Handbook on General Hospital Psychiatry (2004) and Catatonia; From Psychopathology to Neurobiology (2004) and an upcoming book on the connection between depression and heart disease. He is now at work on a book looking at brain evolution, the dialectical relationship between separation and attachment and its importance for medicine and the human experience. Most recently he has been involved in research on neuroimmune mechanisms underlying diseases that connect mind and body. He also has been a reviewer for many major medical journals.
Dr. Goff is Director of the Schizophrenia Clinical and Research Program at Massachusetts General Hospital and Associate Professor of Psychiatry at Harvard Medical School. In addition, he is Medical Director of the Freedom Trail Clinic at the Erich Lindemann Mental Health Center in Boston.
Dr. Goff earned his undergraduate degree in humanities at the University of California in Berkeley, and his medical degree at the University of California School of Medicine in Los Angeles. After graduating, he completed his internship in internal medicine at Cedars Sinai Medical Center in Los Angeles, and his residency in psychiatry at Massachusetts General Hospital in Boston. His research fellowship in psychopharmacology was completed at Tufts-New England Medical Center, also in Boston.
Dr. Goff has authored ore than 180 articles and chapters and lectures nationally and internationally on new treatment approaches in schizophrenia. Dr. Goff established the Schizophrenia Program at the Massachusetts General Hospital in 1988, which has grown under his leadership to include investigators studying pharmacology genetics, neuroimaging, wellness, and cognitive behavioral therapy.
Dr. Goff is a recipient of the Faculty Scholar Award in Schizophrenia and a Mid-Career Development Award presented by the National Institute of Mental Health, and Kempf Award for Mentorship in Biological Psychiatry from the American Psychiatric Association. Dr. Goff is a member of the American College of Neuropharmacology.
Professor and Vice Chairman Department of Psychiatry
Director, Schizophrenia Research Group University of New Mexico
Dr. Lauriello is Professor and Vice Chairman of the Department of Psychiatry at the University of New Mexico (UNM) in Albuquerque, where he also serves as the Executive Medical Director of the UNM Psychiatric Center, Psychiatry Chief of Clinical Operations and Director of the Schizophrenia Research Group. Dr. Lauriello serves as a reviewer for The American Journal of Psychiatry, Journal of Clinical Psychiatry and Schizophrenia Research, among others, and has been an author on over 35 journal articles and 11 chapters and has been a co-editor on several works including the recently published book Atypical Antipsychotics from Bench to Bedside. He has been active in pharmaceutical research funded by private foundations and the National Institute of Health.
He was recognized in the 2001-2002 and 2003-2004 editions of the Best Doctors in America and is a past recipient of the National Alliance for the Mentally Ill Exemplary Psychiatrist Award. In addition, he is a board member of the Biomedical Research Institute of New Mexico. Dr. Lauriello completed his psychiatry residency at New York Hospital-Payne Whitney Clinic, which he followed with fellowships in clinical psychopharmacology at University of California at San Diego and the Stanford University/Palo Alto VAMN. He received his medical degree from Temple University Medical School in Philadelphia, Pennsylvania and is a graduate of Yale College.
Director, Reproductive Endocrine Associates, Massachusetts General Hospital
Assistant Professor of Medicine, Harvard Medical School
She has active teaching and clinical roles in the Unit, and her main clinical interest is in the area of menopause and hormone replacement therapy. Dr. Martin has lectured extensively at MGH, Harvard Medical School, and at national meetings and postgraduate courses on this topic.
Dr. Martin has also directed our group practice, the Reproductive Endocrine Associates, for the past 13 years. In addition to menopause, her other areas of clinical interest include menstrual cycle disorders, polycystic ovary syndrome, and infertility. Her teaching role includes assuming responsibility for much of the clinical training in reproductive endocrinology of the first year endocrinology fellows, post-doctoral fellows who choose to do their subspecialty training in our Unit, and rotating medical house officers. The success and uniqueness of the Reproductive Endocrine Unit's practice was recently highlighted by an invitation by the Journal of Clinical Endocrinology and Metabolism to publish it as a model of an academic/clinical investigative practice. Dr. Martin was the senior author of this publication in recognition of her importance in its function as well as its didactic and scholarly activities.
Despite Dr. Martin's busy clinical and teaching roles, she continues to make major contributions to clinical investigation within our Unit. She has published the only large study comparing efficacy and safety of two types of therapies (including pulsatile GnRH, a therapy pioneered in the REU) for inducing ovulation in women with infertility. More recently, Kathryn was the senior author on two important papers that defined the biochemical abnormalities and natural history of women with hypothalamic amenorrhea (lack of periods due to weight loss, eating disorders, or heavy exercise).
Dr. Andrew A. Nierenberg is Medical Director of the Bipolar Clinic and Research Program and Associate Director of the Depression Clinical and Research Program at Massachusetts General Hospital. Dr. Nierenberg is Professor of Psychiatry at Harvard Medical School.
Dr. Nierenberg is a graduate of the Albert Einstein College of Medicine of Yeshiva University, Bronx, New York. He completed his residency in psychiatry at New York University / Bellevue Hospital in New York City. He next studied clinical epidemiology at Yale University as a Robert Wood Johnson Clinical Scholar. Dr Nierenberg continued his trek north to join the faculty at Harvard Medical School, first to direct one of the Affective Disorders Inpatient Units and then to direct the Affective Disorders Outpatient Unit at McLean Hospital in Belmont, Massachusetts. He then joined the Department of Psychiatry at Massachusetts General Hospital in 1992, where he holds his current positions.
Dr. Nierenberg has published over 200 original articles and has been listed in The Best Doctors In America for the treatment of mood and anxiety disorders in every edition since 1994. In 2000, he was awarded the Gerald L. KlermanYoung Investigator award by the National Depression and Manic-Depressive Association (NDMDA) and two independent Investigator Awards by the National Association for Research in Schizophrenia and Depression (NARSAD). Dr. Nierenberg was elected as a member of the American College of Neuropsychopharmacology in 2005.
Dr. Nierenberg was on the leadership teams of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) and the Sequential Treatment Alternatives to Relieve Depression (STAR*D) National Institute of Mental Health (NIMH) contracts, two unprecedented clinical trials that included thousands of patients with mood disorders. Since October 2005, he has been the PI and Director of the NIMH Bipolar Trials Network.
Dr. Nierenberg’s primary interests are treatment-resistant depression, bipolar depression, juvenile bipolar disorder, and the longitudinal course of affective disorders. He lectures extensively, both nationally and internationally, teaches, maintains an active clinical practice, conducts clinical trials funded by the NIMH and industry, was a member of the NIMH Initial Review Group for Intervention Research and serves as a peer reviewer for over 25 psychiatric journals. He is a member of the editorial board of the Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, International Journal of Neuropsychopharmacology, and Bipolar Disorders.
Disclosures:
Dr. Nierenberg receives research grant support from: NIMH and Pfizer, Inc.
Dr. Nierenberg is an advisor or consultant for: AstraZeneca, BrainCells, Inc., Eli Lilly and Company, Merck and Company, Jazz Pharmaceuticals, NIMH, Novartis, and Schering-Plough.
Dr. Nierenberg is a presenter for the Massachusetts General Hospital Psychiatry Academy. The education programs conducted by the MGH Psychiatry Academy are supported through Independent Medical Education (IME) grants from pharmaceutical companies.
Dr. Petersen spearheads development and implementation of continuing medical education programs delivered by MGH faculty to worldwide providers. Dr. Petersen is the author or co-author of over 60 scholarly articles published in peer-reviewed scientific journals, numerous book chapters, and books. He has been invited to present his research findings at numerous national and international professional meetings and has served as a reviewer for several scientific journals.
Dr. Petersen served as a cognitive therapist and project coordinator for the seminal NIH Sequential Alternatives to Relieve Depression (STAR*D) investigation and was the principal investigator for an investigation sponsored by a Young Investigator Grant received from the National Alliance for Research on Schizophrenia and Depression (NARSAD). In 2002, he was awarded the New Investigator Award by the NIH New Clinical Drug Evaluation Unit.
Dr. Petersen's clinical specialty is cognitive behaviorally based interventions for difficult to treat mood disorders. He is sought after to provide consultation for complex clinical cases. As part of his research work, he has been involved in developing various evidence-based psychotherapy treatment manuals. Dr. Petersen is active in providing clinical and research supervision to MGH psychology interns and psychiatry residents, and has mentored several undergraduate and graduate students during clinical and research practical placements.
Dr. Pollack is Director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, and Professor of Psychiatry at Harvard Medical School. He received his medical degree in 1982 from New Jersey Medical School, and completed residency and fellowship training in psychiatry at Massachusetts General Hospital.
Dr. Pollack has received federal funding from the National Institute of Mental Health (NIMH) and National Institute of Drug Abuse (NIDA) to study the longitudinal course of panic disorder, the application of cognitive-behavioral intervention of benzodiazepine discontinuation in panic disorder patients to the reduction of illicit drug use in drug abusers, the impact of recent terrorist attacks on the development of PTSD and course of disorder in bipolar patients, changes in brain function as assessed by MR Spectroscopy and neuropsychological testing in patients on methadone maintenance, and treatment response and pharmacogenetics in refractory social anxiety disorder, and the use of d-cycloserine to enhance the treatment efficacy of cognitive-behavioral therapy in social anxiety disorder.
He has published over 300 articles, reviews and chapters, and is co-editor of the books Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies, Panic Disorder and it's Treatment, and Social Phobia: Research and Practice. Dr. Pollack is editor-in-chief of the journal CNS Neuroscience and Therapeutics, lectures widely in national and international forums, serves on numerous editorial and advisory boards, as well as the Scientific Advisory Board of the Anxiety Disorders Association of America and the Board of Directors of the Mood and Anxiety Disorders Institute of the Massachusetts General Hospital.
His areas of clinical and research interest include the acute and long-term course, pathophysiology and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.
Dr. Rauch is Associate Professor of Psychiatry at Harvard Medical School and Associate Chief of Psychiatry (for Neuroscience Research) at Massachusetts General Hospital, where he also serves as Director of the Psychiatric Neuroimaging Research Program and the Division of Psychiatric Neuroscience and Neurotherapeutics. As a clinician at Massachusetts General Hospital, he provides consultation regarding neurosurgical candidates as a member of the Psychiatric Neurosurgical Committee. Dr. Rauch has contributed over 200 publications to the scientific literature and currently serves on the editorial boards of four journals. His principal research interests are related to neuroimaging and the neurobiology of mood and anxiety disorders.
Director, Sleep Disorders Center, Henry Ford Hospital
Clinical Professor, Department of Psychiatry. Henry Ford Hospital
Dr. Roth is currently the director of the Sleep Disorders and Research Center at Henry Ford Health Systems in Detroit. In addition to his position at Henry Ford, he is a Clinical Professor of Psychiatry at the University of Michigan School of Medicine in Ann Arbor. He received his doctorate degree from the University of Cincinnati in 1970.
Dr. Roth's research primarily focuses on sleep process. His work includes research on sleep loss, sleep fragmentation, and deviation from sleep processes, including pharmacological effects and sleep pathologies.
Dr. Roth has held numerous leadership positions within his field. He is past chairman of the National Center on Sleep Disorders Research Advisory Board at the National Institutes of Health and past president of the United States Sleep Research Society, the American Sleep Disorders Association, and the National Sleep Foundation. He also served as past editor-in-chief of the journal, Sleep.
He has published over 300 peer-reviewed papers, 13 edited volumes, 142 chapters and 463 abstracts.
Vice Chair, Department of Clinical Sciences
Professor, Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas.
Dr. Rush earned his undergraduate degree at Princeton university and his medical degree at the Columbia College of Physicians and Surgeons Medical School. He completed his internship in internal medicine at Northwestern University and residency in psychiatry at the University of Pennsylvania.
With Research interest primarily devoted to biological and psychosocial issues in mood disorders in adults, children and adolescents, Dr. Rush is particularly interested in promoting the application of clinical research findings to improve the diagnosis and treatment of these patients. He has authored or coauthored more than 470 papers and chapters and 10 books concerning the treatment of depression, the use of vagus nerve stimulation, and the development and feasibility testing of treatment algorithms for depressive, bipolar, and schizophrenic disorder.
Dr. Rush's articles have been published in the American Journal of Psychiatry, Archives of General Psychiatry, Journal of Nuclear Medicine, and Neuropsychopharmacology, and the American Psychiatric Association.
Director, Harvard Bipolar Research Program, Massachusetts General Hospital; Associate Professor of Psychiatry, Harvard Medical School
Kenneth T. Norris, Jr. Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Alan F. Schatzberg received his M.D. from New York University in 1968. He did his psychiatric residency at the Massachusetts Mental Health Center from 1969-1972 and was Chief Resident, Southard Clinic in 1971-1972. He was also a Clinical Fellow in Psychiatry at Harvard Medical School.
After serving in the United States Air Force, he joined the staff at McLean Hospital and the Faculty of Harvard Medical School in 1974. At McLean Hospital, he held a number of important positions including Service Chief, Interim Psychiatrist in Chief, Co-Director of the Affective Disorders Program (with Dr. J. Cole) and Director of the Depression
Research Facility. In 1988, he became Clinical Director of the Massachusetts Mental Health Center and Professor of Psychiatry at Harvard Medical School but continued at McLean Hospital with his research program on the biology and treatment of depression. In 1991, Dr. Schatzberg moved to Stanford University to become the Kenneth T. Norris, Jr., Professor and Chairman of the Department of Psychiatry and Behavioral Sciences.
Dr. Schatzberg has been an active investigator in the biology and psychopharma-cology of depressive disorders. He has explored norepinephrine systems in depression as a means of subtyping these disorders. His research has also given us major insights into the biological mechanisms that underlie the development of delusions in major depression, and is now opening exciting and innovative therapeutic strategies. Dr. Schatzberg has been an active investigator in the clinical psychopharmacology of nondelusional depression with a particular recent interest in chronic depression. He has authored over 450 publications and abstracts, including the Manual of Clinical Psychopharmacology, whose third edition was published in 1997 and which is co-authored by Dr. Jonathan O. Cole and Dr. Charles DeBattista. He also co-edited with Dr. Charles B. Nemeroff the Textbook of Psychopharmacology whose second edition was published in 1998. He is Co-Editor in-Chief of the Journal of Psychiatric Research and sits on many other editorial boards as well, including the American Psychiatric Press, Archives of General Psychiatry, Depression and Anxiety (Associate Editor in Chief), Journal of Clinical Psychopharmacology, and others. He currently is President of the American College of Neuropsychopharmacology and was awarded the 1998 Gerald L. Klerman, M.D. Lifetime Research Award from the NDMDA.
Director, Law & Psychiatry Service,
Massachusetts General Hospital;
Associate Professor of Psychiatry, Harvard Medical School
Professor and Head, Department of Psychiatry, University of Minnesota Medical School,
Medical Staff, University of Minnesota Medical Center
Dr. Schulz performed his undergraduate training at the University of Southern California where he received a Bachelor of Arts in history. Upon graduation, he moved across town to UCLA Medical School where he received his medical degree as well as hid psychiatric training. Following an interest in academic psychiatry, Dr. Schulz became a clinical associate at the National Institute of Mental Health were he worked in the Neuropsychopharmacology section at the Clinical Center. During his clinical associationship, he became interested in clinical trials for patients with schizophrenia as well as research in family issues.
In 1980, Dr. Schulz moved to the Medical College of Virginia where he started the Schizophrenia Program. His research interests focused on neuropsychiatric studies of teenagers suffering from schizophrenia, including CT research. He worked on the research team that investigated the "lowdose neuroleptic" strategy for borderline personality disorder. In 1983, he became Medical Director of the Schizophrenia Module at the university of Pittsburgh where his research focused on treatment refractory schizophrenia. In 1986, he moved to the NIMH extramural program where he contributed to the National Plan on Schizophrenia Research. Along with Dr. Carol Tamminga, he started the biennial International Congress on Schizophrenia Research.
Dr. Schulz was Professor and Chairman of the Department of Psychiatry at Case Western Reserve University School of Medicine and University Hospital of Cleveland from 1989-1999. His research interests were MRI imaging in adolescents with schizophrenia and bipolar illness. He also has been active in clinical trials with antipsychotic medications.
Since 1999, Dr. Schulz has been Professor and Head of the Department of Psychiatry at the University of Minnesota, where he has continued his work in brain imaging as part of the MIND Institute and clinical trials in BPD.
Marion E. Kenworthy Professor of Psychiatry, Columbia University School of Social Work and the College of Physicians and Surgeons
Dr. Shear graduated from the University of Chicago and received her medical degree from Tufts University. She completed residency training in Internal Medicine and Psychiatry and obtained Board Certification from the American Board of Internal Medicine and the American Board of Psychiatry and Neurology. Dr. Shear has conducted treatment studies in panic and other anxiety disorders under grants from the National Institute of Mental Health and pharmaceutical company grants for over 20 years. Dr. Shear recently completed a four-site NIMH-funded study of Long-Term Treatment of Panic Disorder. She served as co-chair of the American Psychiatric Association Guidelines for the Treatment of Panic Disorder, as Editorial Board member of the American Journal of Psychiatry, and as advisor to the National Red Cross Disaster Mental Health services. She has chaired meetings for the Anxiety Disorders Association of America.
Most recently she has turned her attention to studies of bereavement and grief, a neglected area in psychiatric research. She completed the first randomized controlled trial of a novel psychotherapy she developed for Complicated Grief, a newly defined clinical syndrome, and a pilot study of pharmacotherapy for this condition, as well as a pilot medication study and a pilot study of early bereavement-related depression. she has written a treatment manual for Complicated Grief Treatment and consulted on a video production to train clinicians to recognize this syndrome.
Director, Mood Disorders Research Program and Clinic, University of Texas Southwestern Medical Center at Dallas
Lydia Bryant Test Professorship in Psychiatric Research, University of Texas Southwestern Medical Center at Dallas
Dr. Trivedi is currently the Director of the Mood Disorders Research Program and Clinic at the University of Texas Southwestern Medical Center at Dallas where he holds the Lydia Bryant Test Professorship in Psychiatric Research. Dr. Trivedi is an established efficacy and effectiveness researcher in the treatment of depression.
Dr. Trivedi has been a principal investigator in multiple clinical trials funded through NIMH and the Texas Department of Mental Health, as well as the pharmaceutical industry. He has been involved with evidence-based depression guideline development since 1990, when he joined the Depression Guideline Panel of the AHCPR (A. John Rush, MD, Chair).
Dr. Trivedi was a member of the consensus panel for the Texas Medication Algorithm Project (TMAP), which developed the algorithms for major depressive disorder and he has been the Director of the Depression Algorithm for TMAP since its inception. Dr. Trivedi is also currently the Co-Director of the Dallas Coordinating Center of the NIMH funded project titled "Squenced Treatment and Alternatives to Relieve Depression" (STAR*D), of which he is Co-Principal Investigator. Dr. Trivedi is also Principal Investigator of three current NIMH grants entitled "CBASP Augmentation for Treatment of Chronic Depression" (REVAMP), "Treatment with Exercise Augmentation for Depression" (TREAD), and "Computerized Decision Support System for Depression" (CDSS-D).
Dr. Trivedi has mentored many psychopharmacology pstdoctoral fellows and research-track residents over several years in the Depression and Anxiety Disorders Program, which he directs at UT Southwestern Medical Center at Dallas. Dr. Trvedi has served as the chair of the Depression Work Group of the international Psychopharmacology Algorithm Project and as the scientific content expert for the San Antonio Cochrane Center's evidence-based, AHCPR-funded efforts to update the Depression Guidelines.
Dr. Trivedi spearheaded the rollout of best practices for the treatment of MDD in various MMR centers across the state of Texas. Dr. Trivedi is also studying the effectiveness of treatments of depression in primary care.
Dr. Trivedi has received numerous awards including the Gerald L. Klerman award from the National Depressive and Manic-Depressive Association Scientific Advisory Board-NDMDA and the Psychiatric Excellence Award from the Texas Society of Psychiatric Physicians (TSPP). Dr. Trivedi has published more than 180 articles and chapters related to the diagnosis and treatment of mood disorders.
Clinical Director, Alcohol and Drug Abuse Treatment Program, McLean Hospital
Professor of Psychiatry, Harvard Medical School
Dr. Weiss is Professor of Psychiatry at Harvard Medical School and Clinical Director of the Alcohol and Drug Abuse Treatment Program at McLean Hospital. Through his research, international teaching and writings, Dr. Weiss has made significant contributions to the field of substance abuse and dual diagnosis. He is principal investigator on 4 NIDA or NIAAA grants, including the Northern New England Node of the NIDA Clinical Trials Network.
He has authored over 220 articles and book chapters and has recently developed a new group therapy for patients with bipolar disorder and substance dependence. Together with Steven M. Mirin, MD, Dr. Weiss has authored the book Cocaine, and he recently co-edited a book with Drs. Joseph Westermeyer and Douglas Ziedonis entitled Integrated Treatment for Mood and Substance Use Disorders.
Professor of Psychiatry, Yale University
Director, PRIME Clinic, Yale University
Staff Member, Connecticut Mental Health Center, Yale-New Haven Hospital
Dr. Woods is a Professor of Psychiatry at Yale School of Medicine and an expert in the early course of schizophrenia. He is the Director of Yale's PRIME Clinic (Prevention through Risk Identification, Management, and Education), the first research clinic in North America devoted to study of the early, or prodromal, phase of schizophrenia. Dr. Woods is a co-author of two psychometric instruments widely used and translated for the schizophrenia prodrome, the Structured Interview for Prodromal Syndromes (SIPS) and the Scale of Prodromal Symptoms (SOPS). In addition to nearly 200 other scientific publications, Dr. Woods is the principal author of the first publication describing results of a placebo-controlled treatment study for prodromal patients.
He is the first researcher to investigate the possible benefits of NMDA agonists at the glycine/D-serine site in the schizophrenia prodrome. Dr. Woods is also the founder of a new clinic at Yale for first episode psychosis patients, known as the Specialized Treatment Early in Psychosis, or STEP Clinic. Dr. Woods is certified by the American Board of Psychiatry and Neurology (1989) and is a member of the medical staffs of the Connecticut Mental Health Center, Yale-New Haven Hospital, and Hartford Hospital. He is frequently invited to speak at meetings of the American Psychiatric Association and at other venues.
